Massachusetts

Mass Megawatts (MMMW) Plans Solar Tracker Trailer Tour of Small Portable Units Explaining the Cost Benefits

Friday, April 16, 2021 - 12:14pm

b"Boston, Massachusetts--(Newsfile Corp. - April 16, 2021) - Mass Megawatts (OTC Pink: MMMW) www.massmegawatts.com today announces plans to have a solar tracker trailer tour with small solar units to explain the cost and output of the additional solar tracking features.

Key Points: 
  • b"Boston, Massachusetts--(Newsfile Corp. - April 16, 2021) - Mass Megawatts (OTC Pink: MMMW) www.massmegawatts.com today announces plans to have a solar tracker trailer tour with small solar units to explain the cost and output of the additional solar tracking features.
  • The solar units using the tracker reduce the cost of solar power by employing a furling technology borrowed from wind technology for protection in the case of high wind events.
  • The STS allows Mass Megawatts to lower the cost of material and reduce the number of solar panels needed to generate the rated capacity.
  • Mass Megawatts sees an opportunity to be part of the growing solar tracker market with a lower cost product than the trackers marketed by other solar tracker companies in this high growth segment of the solar energy market.

Avery Design Debuts CXL(TM) 2.0 System-level VIP Simulation Solution

Thursday, April 15, 2021 - 1:28pm

b'Tewksbury, Massachusetts--(Newsfile Corp. - April 15, 2021) - Avery Design Systems, a leader in functional verification solutions, today announced its CXLTM 2.0 system-level simulation solution.

Key Points: 
  • b'Tewksbury, Massachusetts--(Newsfile Corp. - April 15, 2021) - Avery Design Systems, a leader in functional verification solutions, today announced its CXLTM 2.0 system-level simulation solution.
  • The comprehensive offering supports the co-simulation of a CXL-aware Linux kernel and QEMU x86 virtual host system emulator with its SystemVerilog CXL Host VIP.
  • The company has established numerous Avery Design VIP partner program affiliations with leading IP suppliers.
  • More information is available at www.avery-design.com .\n'

Embossed NPWT Dressing Successfully Completes Clinical Safety Study

Thursday, April 15, 2021 - 1:24pm

The pump will have a fixed pressure, single button operation and a canister.

Key Points: 
  • The pump will have a fixed pressure, single button operation and a canister.
  • It will be very compact, similar in size to a small mobile phone.\nClick image above to view full announcement.\nApplied Tissue Technologies brings advancements in wound healing to patients.
  • www.appliedtissue.com @npwtsimplified\nThe PWD is supported in part by the United States Defense Health Agency (Small Business Innovation Research), USAMRAA, and USAMRMC through contract numbers W81XWH-18-2-0002, W81XWH-18-C-0143, W81XWH-19-2-0038 and W81XWH-16-0784.
  • The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.\n'

Plymouth Rock Technologies Appoints Dr. Gianluca De Novi to the Role of VP of Engineering

Tuesday, April 13, 2021 - 9:00pm

b'Plymouth, Massachusetts--(Newsfile Corp. - April 13, 2021) - Plymouth Rock Technologies Inc. (CSE: PRT) (OTCQB: PLRTF) (FSE: 4XA) (WKN: A2N8RH) ("Plymouth Rock", "PRT", or the "Company"), a leader in developing threat detection and unmanned technologies, is pleased to announce that Dr. Gianluca De Novi has been appointed to the role of VP of Engineering.\nDr.

Key Points: 
  • b'Plymouth, Massachusetts--(Newsfile Corp. - April 13, 2021) - Plymouth Rock Technologies Inc. (CSE: PRT) (OTCQB: PLRTF) (FSE: 4XA) (WKN: A2N8RH) ("Plymouth Rock", "PRT", or the "Company"), a leader in developing threat detection and unmanned technologies, is pleased to announce that Dr. Gianluca De Novi has been appointed to the role of VP of Engineering.\nDr.
  • De Novi is currently a Harvard Faculty member, Director of the Medical Device and Simulation Laboratory at the Imaging Department of the Massachusetts General Brigham Hospital and CEO at XSurgical Robotics.
  • "Dr. De Novi\'s international experience in the fields of automation and research and his exceptional engineering skills, positions him perfectly to undertake this role," concluded Wheeler.\n"I feel pleased for the new role that was offered to me at Plymouth Rock Technologies.
  • Plymouth Rock products, both airborne and land-based, will scan for threat items at greater \'stand-off\' distances than current existing technologies.

Newbury Street Acquisition Corporation Announces the Separate Trading of its Common Stock and Warrants, Commencing April 16, 2021

Wednesday, April 14, 2021 - 9:15pm

No fractional warrants will be issued upon separation of the units and only whole warrants will trade.

Key Points: 
  • No fractional warrants will be issued upon separation of the units and only whole warrants will trade.
  • The shares of common stock and warrants that are separated will trade on The Nasdaq Stock Market LLC under the symbols "NBST" and "NBSTW," respectively.
  • Those units not separated will continue to trade on The Nasdaq Stock Market LLC under the symbol \xe2\x80\x9cNBSTU\xe2\x80\x9d.
  • Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements.

Data Center Cooling Pioneer LiquidStack Announces Board of Directors

Wednesday, April 14, 2021 - 2:22pm

b'BOSTON, April 14, 2021 (GLOBE NEWSWIRE) -- LiquidStack , the world\xe2\x80\x99s largest liquid cooling company, today announced the formation of its board of directors.

Key Points: 
  • b'BOSTON, April 14, 2021 (GLOBE NEWSWIRE) -- LiquidStack , the world\xe2\x80\x99s largest liquid cooling company, today announced the formation of its board of directors.
  • As Chairman of the Board, Wahid will support LiquidStack\xe2\x80\x99s global growth plans and ambitions.\n\xe2\x80\x9cAfter a 16-year career in power and cooling, I am confident that the future of the data center industry is 2-phase immersion cooling.
  • I could not be more excited to serve as Chairman of the Board for LiquidStack, the original pioneer of immersion cooling technology,\xe2\x80\x9d said Wahid Nawabi, president and CEO of AeroVironment.\nDr.
  • Through cross-licensing arrangement, the companies are already collaborating on new liquid cooling projects related to crypto-mining and artificial intelligence.\nFor more information on the LiquidStack board of directors, please visit www.liquidstack.com/about-us .\nLiquidStack has the world\xe2\x80\x99s largest footprint of liquid cooling for data center, edge and high-performance computing.

Lyndra Therapeutics Presents Promising Phase 2 Data on Once-Weekly Oral Risperidone Treatment, LYN-005, in Development for Schizophrenia

Sunday, April 18, 2021 - 9:20pm

b'Lyndra Therapeutics , a clinical-stage biotechnology company working to make daily pills a thing of the past, today announced results from its Phase 2 study of LYN-005, the Company\xe2\x80\x99s oral, ultra-long-acting, extended-release (ER) risperidone capsule, in development for the weekly treatment of schizophrenia.

Key Points: 
  • b'Lyndra Therapeutics , a clinical-stage biotechnology company working to make daily pills a thing of the past, today announced results from its Phase 2 study of LYN-005, the Company\xe2\x80\x99s oral, ultra-long-acting, extended-release (ER) risperidone capsule, in development for the weekly treatment of schizophrenia.
  • The study included a lead-in period in which patients received IR risperidone tablets (2 mg or 4 mg) for 13 days in order to achieve a steady therapeutic state.
  • It affects approximately 2.2 million U.S. adults, often beginning in the late teens or early twenties.
  • For more information, visit the Company\xe2\x80\x99s website at www.lyndra.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210418005010/en/\n'

Elucid Presents Results of the EVAPORATE Study at ESC Preventive Cardiology 2021 Late Breakers

Saturday, April 17, 2021 - 2:50pm

The study evaluated the change in plaque characteristics using CTA in 55 statin-treated patients having data at all timepoints.

Key Points: 
  • The study evaluated the change in plaque characteristics using CTA in 55 statin-treated patients having data at all timepoints.
  • Advanced clinical insights from ElucidVivo equip physicians with critical information designed to enable precision medicine.
  • This unique information informs better treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs.
  • To learn more visit https://www.elucidbio.com/ and follow us on LinkedIn .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210417005003/en/\n'

Entegris Announces Pricing of $400 Million Offering of 3.625% Senior Unsecured Notes

Friday, April 16, 2021 - 11:47pm

b'Entegris, Inc. (NASDAQ: ENTG) (the \xe2\x80\x9cCompany\xe2\x80\x9d) today announced that it has priced its private offering of $400 million aggregate principal amount of 3.625% senior unsecured notes due 2029 (the \xe2\x80\x9c2029 Notes\xe2\x80\x9d).

Key Points: 
  • b'Entegris, Inc. (NASDAQ: ENTG) (the \xe2\x80\x9cCompany\xe2\x80\x9d) today announced that it has priced its private offering of $400 million aggregate principal amount of 3.625% senior unsecured notes due 2029 (the \xe2\x80\x9c2029 Notes\xe2\x80\x9d).
  • The 2029 Notes will be senior unsecured obligations of the Company and will be guaranteed by certain subsidiaries of the Company.
  • The sale of the 2029 Notes is expected to close on April 30, 2021, subject to customary closing conditions.\nThe Company expects the net proceeds of the offering to be approximately $394 million, after deducting estimated commissions and offering fees and expenses.
  • The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210416005580/en/\n'

Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Friday, April 16, 2021 - 9:30pm

Each of the options was granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).\nVicineum, a locally administered fusion protein, is Sesen Bio\xe2\x80\x99s lead product candidate being developed for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

Key Points: 
  • Each of the options was granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).\nVicineum, a locally administered fusion protein, is Sesen Bio\xe2\x80\x99s lead product candidate being developed for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
  • In prior clinical trials conducted by Sesen Bio, EpCAM has been shown to be overexpressed in NMIBC cells with minimal to no EpCAM expression observed on normal bladder cells.
  • Sesen Bio is currently in the follow-up stage of a Phase 3 registration trial in the US for the treatment of BCG-unresponsive NMIBC.
  • Additionally, Sesen Bio believes that cancer cell-killing properties of Vicineum promote an anti-tumor immune response that may potentially combine well with immuno-oncology drugs, such as checkpoint inhibitors.